Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The National Cancer Moonshot - NIH - directing ONCY's focus

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 10, 2021 12:26pm

194 Views

Post# 34219039

RE:The National Cancer Moonshot - NIH - directing ONCY's focus

Interesting that Andrew de Guttadauro didn't have the foresight to take advantage of a PACT collaboration that Candel Therapeutics has in the below referenced announcement. What other opportunities has de Guttadauro been missing?

https://www.biospace.com/article/releases/candel-therapeutics-and-partnership-for-accelerating-cancer-therapies-pact-to-collaborate-on-lung-cancer-trial-for-can-2409/

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta